



HEB

**Journal of Hospital Pharmacy**  
An Official Publication of Bureau for Health & Education Status Upliftment  
(Constitutionally Entitled As Health-Education, Bureau)

JOHP

## Uncovering the Complexity of Neurodegenerative Disorders: Clinical Presentation and Diagnosis

*Ajeet Singh, Mo. Mazhar, Sachin Chauhan, Himanshu Chand Kaushik, Dr. Manju Pandey*

Institute of Pharmacy, SRMU Lucknow-Deva Road Barabanki

\*Correspondence: Dr. Syed Zia Inamdar, Professor & Head, Department of Pharmacy Practice, BLDEAs Shri Sanganabasava Mahaswamiji College of Pharmacy and Research Centre, Vijayapura 586103, Karnataka, India

Email Id: [serviceheb@gmail.com](mailto:serviceheb@gmail.com)

### Abstract:

Neurodegenerative diseases (NDDs) represent a heterogeneous group of chronic, progressive disorders characterized by the selective loss of neuronal structure and function. Driven primarily by demographic shifts and increased global life expectancy, NDDs—led by Alzheimer's Disease (AD) and Parkinson's Disease (PD)—constitute one of the most significant public health crises of the 21st century. The accurate and early diagnosis of NDDs is critical for optimizing treatment, managing expectations, and facilitating enrollment in disease-modifying therapeutic trials. The foundation of diagnosis remains the detailed recognition of core clinical presentations. These can be broadly categorized into cognitive syndromes, typified by the Alzheimer's spectrum (e.g., episodic memory loss, executive dysfunction), and motor syndromes, encapsulated by the Parkinsonian syndromes (e.g., bradykinesia, rigidity, resting tremor). Crucially, the differentiation of classical PD from Atypical Parkinsonian Syndromes (APS) like Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA) is vital due to distinct prognoses and treatment responses. Furthermore, the recognition of non-motor symptoms (NMS) in PD, such as REM Sleep Behavior Disorder (RBD), and the behavioral changes dominating Frontotemporal Dementia (FTD) are essential for accurate phenotypic classification. Modern diagnosis transcends clinical observation through the integration of a powerful diagnostic toolkit. Structural Neuroimaging (MRI) is mandatory, primarily to exclude reversible mimics (e.g., Normal Pressure Hydrocephalus, tumors) and to identify specific patterns of regional atrophy, such as medial temporal lobe atrophy in AD or the 'hummingbird sign' in PSP. Functional Neuroimaging (PET/SPECT) provides biological confirmation: Amyloid and Tau PET visualize the defining pathology of AD, while DaTscan (SPECT) assesses striatal dopamine depletion to differentiate PD from essential tremor. Complementing imaging, Cerebrospinal Fluid (CSF) analysis measures specific protein biomarkers, yielding the characteristic AD signature of low  $\beta$ -Amyloid 42 and high Phosphorylated Tau (p-Tau). Finally, Neuropsychological Assessment provides objective, quantitative measurement of cognitive domains, distinguishing between Mild Cognitive Impairment (MCI) and dementia.

The diagnostic landscape is complicated by differential diagnosis pitfalls, including reversible causes (e.g., Vitamin B12 deficiency), and the increasing prevalence of mixed pathologies (e.g., AD and vascular disease). Looking forward, the field is being revolutionized by emerging technologies. Blood-based biomarkers, such as highly specific plasma p-Tau217, are poised to become cost-effective, first-line screening tools. Concurrently, Artificial Intelligence (AI) is enhancing the precision of imaging analysis and developing predictive models for disease progression. Ultimately, the modern diagnosis of NDDs is a dynamic, integrated process that translates clinical symptoms into biologically confirmed pathology, ensuring patients benefit from timely, targeted management strategies.

### Access this Article Online

Website: <http://www.journalofhospitalpharmacy.in>

Quick Response Code:

Received on 20/11/2025

Accepted on 28/11/2025 © HEB All rights reserved



**KEYWORDS-** Neurodegenerative, Parkinsonian, Cerebrospinal Fluid, Neuropsychological Assessment, Multiple System Atrophy